missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ SCK Polyclonal Antibody

Rabbit Polyclonal Antibody
Brand: Invitrogen™ PA5106744
This item is not returnable.
View return policy
Description
Antibody detects endogenous levels of total SHC2.
Src homology 2 (SH2) domains bind specifically to tyrosine-phosphorylated proteins that temporally participate in signal transduction events. Shc-like protein (Sck) is a neuronal adaptor protein that contains an N-terminal PTB (phosphotyrosine binding) domain, a collagen homology (CH) domain, and a conserved C-terminal SH2 domain. Human Sck transcripts are present at high levels in liver, pancreas, prostate and ovary. In vascular endothelial cells, Sck participates in VEGF-induced signal transduction. Treatment of human umbilical vein endothelial (HUVEC) cells with VEGF induces recruitment of Sck to tyrosine-1175 of the kinase insert domain-containing receptor (KDR) and enhances Sck tyrosine phosphorylation.
Specifications
| SCK | |
| Polyclonal | |
| Unconjugated | |
| SHC2 | |
| 6720466E06; neuronal Shc adaptor homolog; protein Sck; Protein Sli; SCK; SH2 domain protein C2; SHC (Src homology 2 domain containing) transforming protein 2; SHC adaptor protein 2; SHC2; ShcB; SHC-transforming protein 2; SHC-transforming protein B; SLI; src homology 2 domain-containing transforming protein C2; src homology 2 domain-containing-transforming protein C2 | |
| Rabbit | |
| Affinity Chromatography | |
| RUO | |
| 25759, 314612 | |
| -20°C | |
| Liquid |
| Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry | |
| 1 mg/mL | |
| PBS with 50% glycerol and 0.02% sodium azide; pH 7.4 | |
| O70142, P98077 | |
| SHC2 | |
| A synthesized peptide derived from human SHC2(Accession P98077), corresponding to amino acid residues A297-P347. | |
| 100 μL | |
| Primary | |
| Human, Rat | |
| Antibody | |
| IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction